Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | CCR5 | P51681 | 1/20 | 0.42 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.36 |
| ▸ | METAP2 | P50579 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.32 |
| ▸ | CCR8 | P51685 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17429949 | 0.80 | TGFBR1 (0.38) | CCR1RAB9ACCR5TGFBR1CYP1A2 | |
| SCHEMBL29792042 | 0.80 | TGFBR1 (0.38) | CCR1RAB9ACCR5TGFBR1CYP1A2 | |
| SCHEMBL20416958 | 0.79 | CCR1 (0.44) | CCR1RAB9ACCR5METAP2CYP1A2 | |
| SCHEMBL11025602 | 0.77 | CCR1 (0.42) | CCR1RAB9ACCR5METAP2CYP1A2 | |
| SCHEMBL22445332 | 0.77 | CCR1 (0.42) | CCR1RAB9ACCR5METAP2CYP1A2 | |
| SCHEMBL24552639 | 0.76 | KDM4E (0.45) | CCR1RAB9ACCR5METAP2CYP1A2 | |
| SCHEMBL17429948 | 0.75 | TGFBR1 (0.36) | CCR1RAB9ACCR5TGFBR1 | |
| SCHEMBL20938996 | 0.73 | — | — | |
| SCHEMBL31019939 | 0.71 | CYP1A2 (0.38) | CCR1RAB9ACCR5CYP1A2CCR8 | |
| SCHEMBL3237571 | 0.71 | HRH4 (0.40) | CCR1RAB9ACCR5MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250051316-A1 | 2-(ARYL-2-YL) MORPHOLINE AND DEUTERATED DERIVATIVE THEREOF, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | SHANGHAI HANSOH BIOMEDICAL CO., LTD. (CN) | 2025-02-13 | — | — | US | disclosed |
| EP-4428128-A1 | 2-(ARYL-2-YL) MORPHOLINE AND DEUTERATED DERIVATIVE THEREOF, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Shanghai Hansoh Biomedical Co., Ltd. (CN) | 2024-09-11 | — | — | EP | disclosed |
| CN-118176185-A | 2- (Aryl-2-yl) morpholine and deuterated derivative thereof, preparation method and application | 上海翰森生物医药科技有限公司 | 2024-06-11 | — | — | CN | disclosed |
| WO-2023078392-A1 | 2-(ARYL-2-YL) MORPHOLINE AND DEUTERATED DERIVATIVE THEREOF, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 上海翰森生物医药科技有限公司 | 2023-05-11 | — | — | WO | disclosed |
| WO-2023078392-A1 | 2-(ARYL-2-YL) MORPHOLINE AND DEUTERATED DERIVATIVE THEREOF, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 上海翰森生物医药科技有限公司 | 2023-05-11 | — | — | WO | disclosed |
| US-9822124-B2 | Bicyclic heteroaromatic carboxamide compounds useful as Pim kinase inhibitors | INCYTE CORPORATION (US) | 2017-11-21 | — | — | US | disclosed |
| US-20160009726-A1 | BICYCLIC HETEROAROMATIC CARBOXAMIDE COMPOUNDS USEFUL AS PIM KINASE INHIBITORS | INCYTE CORPORATION | 2016-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250051316-A1 | 2-(ARYL-2-YL) MORPHOLINE AND DEUTERATED DERIVATIVE THEREOF, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | TAAR1, TAAR5, AVPR2 | CCR1 1368/4885RAB9A 3365/4885CCR5 748/4885 |
| US-20160009726-A1 | BICYCLIC HETEROAROMATIC CARBOXAMIDE COMPOUNDS USEFUL AS PIM KINASE INHIBITORS | PIM1, PIM2, PIM3 | CCR1 4321/4885RAB9A 3960/4885CCR5 3929/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.